Laura Stronati

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/106761/publications.pdf

Version: 2024-02-01

67 papers	5,140 citations	136740 32 h-index	102304 66 g-index
67 all docs	67 docs citations	67 times ranked	11269 citing authors

#	Article	IF	Citations
1	Innovative method to grow the probiotic Lactobacillus reuteri in the omega3-rich microalga Isochrysis galbana. Scientific Reports, 2022, 12, 3127.	1.6	1
2	Colonic inflammation accelerates the progression of liver disease: A protective role of dipotassium glycyrrhizate. Digestive and Liver Disease, 2022, 54, 1084-1093.	0.4	2
3	Fecal and mucosal microbiota profiling in pediatric inflammatory bowel diseases. European Journal of Gastroenterology and Hepatology, 2021, 33, 1376-1386.	0.8	12
4	Emerging Roles of Gut Virome in Pediatric Diseases. International Journal of Molecular Sciences, 2021, 22, 4127.	1.8	20
5	Fecal High-Mobility Group Box 1 as a Marker of Early Stage of Necrotizing Enterocolitis in Preterm Neonates. Frontiers in Pediatrics, 2021, 9, 672131.	0.9	10
6	SERPINB12 as a possible marker of steroid dependency in children with eosinophilic esophagitis: A pilot study. Digestive and Liver Disease, 2020, 52, 158-163.	0.4	2
7	Necroptosis in Intestinal Inflammation and Cancer: New Concepts and Therapeutic Perspectives. Biomolecules, 2020, 10, 1431.	1.8	30
8	Intestinal Inflammation Alters the Expression of Hepatic Bile Acid Receptors Causing Liver Impairment. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 189-196.	0.9	12
9	Recent advances in potential targets for eosinophilic esophagitis treatments. Expert Review of Clinical Immunology, 2020, 16, 421-428.	1.3	3
10	Mucosal healing in Crohnâ€™s disease: new insights. Expert Review of Gastroenterology and Hepatology, 2020, 14, 335-345.	1.4	13
11	Functional analysis of gut microbiota and immunoinflammation in children with autism spectrum disorders. Digestive and Liver Disease, 2019, 51, 1366-1374.	0.4	38
12	Low Dose of Dipotassium Glycyrrhizate Counteracts Atherosclerosis Progression in ‹b›‹i›Apoeâ€“/â€“‹/i›‹/b› Female Mice. Journal of Vascular Research, 2019, 56, 267-270.	0.6	1
13	Next-Generation Metagenomics: Methodological Challenges and Opportunities. OMICS A Journal of Integrative Biology, 2019, 23, 327-333.	1.0	47
14	Dipotassium Glycyrrhizate Improves Intestinal Mucosal Healing by Modulating Extracellular Matrix Remodeling Genes and Restoring Epithelial Barrier Functions. Frontiers in Immunology, 2019, 10, 939.	2.2	22
15	Quantitative Assessment of Shotgun Metagenomics and 16S rDNA Amplicon Sequencing in the Study of Human Gut Microbiome. OMICS A Journal of Integrative Biology, 2018, 22, 248-254.	1.0	159
16	Transcription Factor ZNF281: A Novel Player in Intestinal Inflammation and Fibrosis. Frontiers in Immunology, 2018, 9, 2907.	2.2	20
17	NOD2 and inflammation: current insights. Journal of Inflammation Research, 2018, Volume 11, 49-60.	1.6	121
18	Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players?. Archives of Medical Science, 2018, 1, 81-87.	0.4	78

#	Article	IF	Citations
19	Faecal high mobility group box 1 in children with celiac disease: A pilot study. Digestive and Liver Disease, 2018, 50, 916-919.	0.4	10
20	Serum Markers of Necrotizing Enterocolitis: A Systematic Review. Journal of Pediatric Gastroenterology and Nutrition, 2017, 65, e120-e132.	0.9	28
21	RIP3 AND pMLKL promote necroptosis-induced inflammation and alter membrane permeability in intestinal epithelial cells. Digestive and Liver Disease, 2017, 49, 1201-1210.	0.4	56
22	Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway. PLoS ONE, 2016, 11, e0157246.	1.1	50
23	NOD2 Is Regulated By Mir-320 in Physiological Conditions but this Control Is Altered in Inflamed Tissues of Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 315-326.	0.9	56
24	Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission. Inflammatory Bowel Diseases, 2016, 22, 2886-2893.	0.9	42
25	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. American Journal of Human Genetics, 2016, 98, 857-868.	2.6	21
26	The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase. Journal of Medicinal Chemistry, 2016, 59, 4867-4880.	2.9	100
27	NOD2 induces autophagy to control AIEC bacteria infectiveness in intestinal epithelial cells. Inflammation Research, 2016, 65, 803-813.	1.6	37
28	Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. Expert Review of Gastroenterology and Hepatology, 2016, 10, 393-403.	1.4	25
29	Krill oil reduces intestinal inflammation by improving epithelial integrity and impairing adherent-invasive Escherichia coli pathogenicity. Digestive and Liver Disease, 2016, 48, 34-42.	0.4	35
30	Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. PLoS ONE, 2016, 11, e0168216.	1.1	83
31	Apoptosis, Necrosis, and Necroptosis in the Gut and Intestinal Homeostasis. Mediators of Inflammation, 2015, 2015, 1-10.	1.4	110
32	LPS-induced TNF-Î± factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. Oncotarget, 2015, 6, 41434-41452.	0.8	100
33	Dipotassium glycyrrhizate via HMGB1 or AMPK signaling suppresses oxidative stress during intestinal inflammation. Biochemical Pharmacology, 2015, 97, 292-299.	2.0	29
34	Micronuclei and chromosome aberrations in subjects occupationally exposed to antineoplastic drugs: a multicentric approach. International Archives of Occupational and Environmental Health, 2015, 88, 683-695.	1.1	37
35	Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease. Expert Review of Molecular Diagnostics, 2014, 14, 763-771.	1.5	22
36	Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with <scp>IBS</scp>. Neurogastroenterology and Motility, 2014, 26, 196-204.	1.6	54

#	Article	IF	Citations
37	Role of HMGB1 as a Suitable Biomarker of Subclinical Intestinal Inflammation and Mucosal Healing in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 1448-1457.	0.9	66
38	Advances in the medical management of paediatric IBD. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 99-108.	8.2	35
39	Necroptosis Is Active in Children With Inflammatory Bowel Disease and Contributes to Heighten Intestinal Inflammation. American Journal of Gastroenterology, 2014, 109, 279-287.	0.2	170
40	Endoplasmic reticulum stress and unfolded protein response are involved in paediatric inflammatory bowel disease. Digestive and Liver Disease, 2014, 46, 788-794.	0.4	21
41	Lactoferrin prevents invasion and inflammatory response following E. coli strain LF82 infection in experimental model of Crohn's disease. Digestive and Liver Disease, 2014, 46, 496-504.	0.4	31
42	Lactobacillus reuteri ATCC55730 in Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 81-86.	0.9	56
43	Associations between Genetic Polymorphisms in IL-33, IL1R1 and Risk for Inflammatory Bowel Disease. PLoS ONE, 2013, 8, e62144.	1.1	75
44	Dipotassium Glycyrrhizate Inhibits HMGB1-Dependent Inflammation and Ameliorates Colitis in Mice. PLoS ONE, 2013, 8, e66527.	1.1	54
45	Paediatric ulcerative colitisâ€"can we predict proctocolectomy?. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 494-495.	8.2	3
46	Interactions Between Intestinal Microbiota and Innate Immune System in Pediatric Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2012, 46, S64-S66.	1.1	30
47	Association Study of a Polymorphism in Clock GenePERIOD3and Risk of Inflammatory Bowel Disease. Chronobiology International, 2012, 29, 994-1003.	0.9	38
48	Usefulness of single-balloon enteroscopy in pediatric Crohn's disease. Gastrointestinal Endoscopy, 2012, 75, 80-86.	0.5	52
49	Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 913-924.	0.9	98
50	Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2012, 35, 327-334.	1.9	219
51	Fecal HMGB1 Is a Novel Marker of Intestinal Mucosal Inflammation in Pediatric Inflammatory Bowel Disease. American Journal of Gastroenterology, 2011, 106, 2029-2040.	0.2	112
52	Usefulness of wireless capsule endoscopy in paediatric inflammatory bowel disease. Digestive and Liver Disease, 2011, 43, 220-224.	0.4	40
53	A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project. BMC Public Health, 2011, 11, 195.	1.2	22
54	Incidence in pediatric IBD is rising: Help from health administrative data. Inflammatory Bowel Diseases, 2011, 17, 1048-1049.	0.9	8

#	Article	IF	Citations
55	New Insights Into the Pathogenesis of Inflammatory Bowel Disease: Transcription Factors Analysis in Bioptic Tissues From Pediatric Patients. Journal of Pediatric Gastroenterology and Nutrition, 2011, 52, 271-279.	0.9	14
56	Methotrexate in paediatric ulcerative colitis: a retrospective survey at a single tertiary referral centre. Alimentary Pharmacology and Therapeutics, 2010, 32, 1017-1022.	1.9	19
57	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 2010, 42, 1118-1125.	9.4	2,284
58	Altered expression of innate immunity genes in different intestinal sites of children with ulcerative colitis. Digestive and Liver Disease, 2010, 42, 848-853.	0.4	28
59	Crohnâ€™s Disease in Children. , 2010, , 169-185.		0
60	Activation of NOD2-mediated intestinal pathway in a pediatric population with CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2009, 15, 1145-1154.	0.9	50
61	Pediatric Inflammatory Bowel Diseases and the Risk of Lymphoma: Should We Revise Our Treatment Strategies?. Journal of Pediatric Gastroenterology and Nutrition, 2009, 48, 257-267.	0.9	40
62	Mucosal NOD2 expression and NF-ÎºB activation in pediatric CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2008, 14, 295-302.	0.9	32
63	Chromosome aberrations and telomere length modulation in bone marrow and spleen cells of melphalanâ€treated p53+/â^' mice. Environmental and Molecular Mutagenesis, 2008, 49, 467-475.	0.9	8
64	Radioresistance in a tumour cell line correlates with radiation inducible Ku 70/80 end-binding activity. International Journal of Radiation Biology, 2008, 84, 265-276.	1.0	11
65	Use of chromosome painting for detecting stable chromosome aberrations induced by melphalan in mice. Environmental and Molecular Mutagenesis, 2005, 45, 419-426.	0.9	6
66	Evaluation of chromosome painting to assess the induction and persistence of chromosome aberrations in bone marrow cells of mice treated with benzene. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 545, 1-9.	0.4	7
67	Expression and DNA binding activity of the Ku heterodimer in bladder carcinoma. Cancer, 2001, 92, 2484-2492.	2.0	25